

EFPIA DISCLOSURE HUNGARY 2017 - SCHEDULE 2													
Published on behalf of Bristol-Myers Squibb (Hungary)													
	Full Name <i>(Art. 1.01)</i>	HCPS: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier OPTIONAL <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL (VAT incl.)	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPS	INDIVIDUAL NAMED DISCLOSURE - one line per HCP												
	Dr. Kardos Tamás	Debrecen	Hungary	4028, Szigligeti u. 8. I/4.	HU	N/A	N/A	0	0	486 728	0	486 728	
	Dr. Csejtei András	Szombathely	Hungary	9700, KEMÉNY ZSIGMOND UTCA 38.	HU	N/A	N/A	0	0	100 000	0	100 000	
	Dr. Varga Fatima	Budapest	Hungary	1023, Hóvirág út 40	HU	N/A	N/A	0	0	127 000	0	127 000	
	Dr. Árkossy Péter	Debrecen	Hungary	4028, Simonyi u. 7. fsz. 1.	HU	N/A	N/A	0	0	127 000	0	127 000	
	OTHER, NOT INCLUDED ABOVE												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A	0	0	4 254 996	0	4 254 996
Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A	0	0	30	0	30	
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						N/A	N/A	0%	0%	88%	0%	88%	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO												
	OTHER, NOT INCLUDED ABOVE												
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						0	13 512 800	0	0	622 300	0	14 135 100
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						0	3	0	0	1	0	3
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						0%	100%	0%	0%	100%	0%	100%	
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											0	0